ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2024
Multimodal Data Integration Improves Disease Risk Prediction in the UK Biobank.
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Family health history is an important component to assess risk for common chronic diseases. The integration of electronic health records and genetic data offers great potential to improve disease risk prediction by capturing both clinical and genetic risk factors. We present ALIGATEHR-Gen, a graph attention network that integrates multimodal patient data including genetic information, diagnosis codes, and demographics, along with external medical ontology knowledge. ALIGATEHR-Gen constructs unified patient representations by incorporating genetically inferred first-degree relationships and disease ontology embeddings to enhance disease risk prediction. We evaluate the predictive performance of ALIGATEHR-Gen across 118 diseases in the UK Biobank and demonstrate that it outperforms state-of-the-art baseline models by an average of at least 6%. A case study on five primary fibrotic and closely related diseases reveals that ALIGATEHR-Gen effectively distinguishes patient subgroups based on clinical and genetic features. These findings illustrate the potential of ALIGATEHR-Gen to advance predictive and interpretable modeling in healthcare.
Indexed as
Identifiers
41726445PMC12919468What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.